

## Novel Target for Drugs that Manipulate Ovulation for Contraception, Infertility and Maintenance of Ovarian Reserve

### Description of Technology

The invention comprises the concept of exploiting the receptor responsible for the transmission of all oocyte-paracrine growth factors to follicular granulosa cells, which, in turn, regulates folliculogenesis and ovulation. This receptor is known as the BMPRII receptor. Agonists and antagonists of this receptor could be embodied in a product that manipulates ovulation for the purpose of fertility management (contraception or increased fertility) in humans and animals or in vitro maturation of oocytes for assisted reproduction (maintenance of ovarian reserve for women who delay childbirth). This technology is currently protected by a PCT application, filed in April 2004. (PCT/AU2004/000455).

### Commercial Applications

There are several avenues by which this receptor could be utilised to manage or modulate fertility. Such methods may facilitate the development of contraceptives or fertility enhancers for human use, methods to manage fertility in animals (either as a contraceptive or augmentation of litter size), novel IVM media formulations/additives for assisted reproductive therapies and/or therapeutics for the maintenance of ovarian reserve.

We are seeking licence partners for this technology in all or restricted fields of application. Potential licencees include embryo culture media companies interested in developing novel IVM media formulations or companies with a focus on contraceptives, women's health and fertility products.

### For Further Details

Please contact: Dr Elaine Stead  
**Adelaide Research and Innovation Pty Ltd**  
GPO Box 149, Rundle Mall  
Adelaide SA 5000 Australia  
Telephone: +61 8 8303 6253  
Facsimile: +61 8 8303 4355  
Email: [elaine.stead@adelaide.edu.au](mailto:elaine.stead@adelaide.edu.au)